VANCOUVER, July 10 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced the completion of enrolment in its Central Venous Catheter (CVC) Pivotal Study, which is designed to examine the safety and efficacy of Angiotech's 5-Fluorouracil (5-FU) coated CVC in preventing bacterial catheter colonization when compared to another leading anti-infective CVC.
